Effects of Polyclonal IgG Derived from Patients with Different Clinical Types of the Antiphospholipid Syndrome on Monocyte Signaling Pathways
Anastasia Lambrianides(Cyprus Institute of Neurology and Genetics), Ian Giles(University College Hospital), Anisur Rahman(University College London), David Isenberg(Regenerative Medicine Institute), Paul A. Townsend(University College London), Jurhee Rice(University of Utah), Charis Pericleous(British Society for Rheumatology), David S. Latchman(Laboratory of Molecular Genetics), Ware Branch(University of Utah), Silvia S. Pierangeli(The University of Texas Medical Branch at Galveston), Christopher J. Carroll(St George's, University of London)
Cited by 80
Related Papers
Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis
|Annals of the Rheumatic Diseases|2012|1k
Treat-to-target in systemic lupus erythematosus: recommendations from an international task force
|Annals of the Rheumatic Diseases|2014|726
Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2/3, non-inferiority trial
|The Lancet Haematology|2016|404
Effective treatment of mitochondrial myopathy by nicotinamide riboside, a vitamin B3
|EMBO Molecular Medicine|2014|386